Satellos Bioscience (MSLE) Liabilities and Shareholders Equity (2023 - 2026)

Satellos Bioscience (MSLE) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $75.2 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed N/A year-over-year to $75.2 million in Q1 2026; TTM through Mar 2026 was $159.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $31.9 million, down 38.99% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $75.2 million, up from $31.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MSLE reached as high as $75.2 million in Q1 2026 and fell as low as $31.9 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $48.0 million across 4 years, with a median of $42.4 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity surged 60.64% in 2024 and plunged 38.99% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $32.5 million in 2023, then surged by 60.64% to $52.3 million in 2024, then slumped by 38.99% to $31.9 million in 2025, then surged by 135.9% to $75.2 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $75.2 million in Q1 2026, $31.9 million in Q4 2025, and $52.3 million in Q4 2024.